MOTS-c is a 16-amino acid mitochondrial-derived peptide that has gained significant attention as a potential exercise mimetic and metabolic regulator. First identified in 2015, it activates AMPK — a central energy-sensing enzyme — and has been shown in preclinical studies to enhance glucose uptake, improve insulin sensitivity, boost physical performance, and support metabolic adaptation in ways that parallel the benefits of exercise. Endogenous MOTS-c levels have been documented to decline with age in both rodent and human tissues, making it a compelling focus for research at the intersection of metabolism, physical performance, and healthy ageing. For researchers studying mitochondrial biology and metabolic resilience, MOTS-c is one of the most exciting molecules to emerge in the past decade.
MOTS-C 20mg
£45.00
About MOTS-C 20mg
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c) is a 16-amino acid peptide encoded within the mitochondrial genome — specifically the 12S rRNA gene. First identified and characterised by the Lee laboratory at the University of Southern California in 2015, MOTS-c belongs to a class of signalling molecules known as mitochondrial-derived peptides (MDPs). Its discovery reshaped understanding of the mitochondrial genome, demonstrating that mitochondrial DNA encodes not just structural components of the electron transport chain but also bioactive peptides with systemic regulatory functions.
MOTS-c has attracted significant research attention for its role as a potential exercise mimetic and metabolic regulator. In published studies, it has been shown to activate AMP-activated protein kinase (AMPK), a central energy-sensing enzyme that coordinates cellular responses to metabolic stress. This AMPK activation underpins many of the downstream effects observed in MOTS-c research, including enhanced glucose uptake, improved insulin sensitivity, and altered lipid metabolism. For researchers studying metabolic regulation, cellular stress responses, and the biology of ageing, MOTS-c represents a uniquely compelling molecule — one that connects mitochondrial signalling to whole-organism physiology.
Research Summary
The foundational study by Lee et al., published in Cell Metabolism in 2015, introduced MOTS-c as a novel mitochondrial-derived peptide and demonstrated its metabolic activity in mouse models. Mice treated with MOTS-c showed improved glucose handling and resistance to diet-induced obesity. The researchers identified AMPK activation as a primary mechanism, positioning MOTS-c as an endogenous regulator that links mitochondrial function to systemic metabolism. This discovery also expanded the concept of MDPs as a class, following earlier identification of humanin and small humanin-like peptides (SHLPs) from other regions of the mitochondrial genome.
The exercise mimetic properties of MOTS-c have been a particularly active area of investigation. In mouse models, administration of MOTS-c has been shown to improve physical performance and metabolic fitness in ways that parallel the benefits of exercise training. Research from the Lee group demonstrated that MOTS-c levels increase in skeletal muscle during exercise in both mice and humans, suggesting that the peptide may function as an endogenous mediator of exercise-induced metabolic adaptation. These findings have made MOTS-c a focal point for researchers interested in the molecular mechanisms that connect physical activity to metabolic health.
One of the more intriguing aspects of MOTS-c biology is its capacity for nuclear translocation under conditions of metabolic stress. Work from the Lee laboratory showed that in response to cellular stress — including glucose restriction and oxidative challenge — MOTS-c translocates from the cytoplasm to the nucleus, where it interacts with transcription factors and influences gene expression. This nuclear role suggests that MOTS-c functions not merely as a circulating hormone but as a direct regulator of the adaptive stress response at the genomic level, bridging mitochondrial signalling and nuclear gene regulation.
Research into MOTS-c and insulin sensitivity has produced noteworthy results across several model systems. In high-fat diet mouse models, MOTS-c administration improved insulin signalling and reduced markers of metabolic dysfunction. Studies have also explored MOTS-c’s effects on skeletal muscle glucose metabolism, finding that it enhances glucose uptake through AMPK-dependent pathways. These observations have positioned the peptide as a research tool for studying insulin resistance mechanisms and the metabolic crosstalk between mitochondria and insulin-responsive tissues.
An age-related decline in endogenous MOTS-c levels has been documented in both rodent and human studies, adding a gerontological dimension to the research. Circulating MOTS-c concentrations appear to decrease with age, correlating with the broader decline in mitochondrial function that characterises ageing. This has prompted investigation into whether MOTS-c supplementation in aged mouse models can reverse age-associated metabolic deterioration. Early results suggest improvements in physical performance and metabolic parameters in older animals, opening a research avenue that intersects ageing biology with mitochondrial peptide science.
The broader class of mitochondrial-derived peptides — of which MOTS-c is a prominent member alongside humanin and the SHLPs — represents a paradigm shift in how researchers view the mitochondrial genome. Once considered primarily a blueprint for oxidative phosphorylation machinery, mitochondrial DNA is now understood to encode a family of bioactive peptides with diverse physiological roles spanning metabolism, stress resistance, and cellular survival. MOTS-c’s continued study is contributing to this evolving picture, and ongoing research aims to further elucidate its receptor interactions, tissue-specific effects, and potential as a probe for investigating the mitochondrial contribution to systemic metabolic regulation.
There are no reviews yet.